BRPI0510114B8 - cristais do composto 4-oxoquinolina, cristais misturados e composição farmacêutica - Google Patents

cristais do composto 4-oxoquinolina, cristais misturados e composição farmacêutica

Info

Publication number
BRPI0510114B8
BRPI0510114B8 BRPI0510114A BRPI0510114A BRPI0510114B8 BR PI0510114 B8 BRPI0510114 B8 BR PI0510114B8 BR PI0510114 A BRPI0510114 A BR PI0510114A BR PI0510114 A BRPI0510114 A BR PI0510114A BR PI0510114 B8 BRPI0510114 B8 BR PI0510114B8
Authority
BR
Brazil
Prior art keywords
crystals
pharmaceutical composition
oxoquinoline compound
crystal
mixed
Prior art date
Application number
BRPI0510114A
Other languages
English (en)
Portuguese (pt)
Inventor
Uehara Ideto
Kondo Kentaro
Ando Koji
Matsuda Koji
Satoh Motohide
Miyake Shuji
Motomura Takahisa
Matsuda Takashi
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0510114(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of BRPI0510114A publication Critical patent/BRPI0510114A/pt
Publication of BRPI0510114B1 publication Critical patent/BRPI0510114B1/pt
Publication of BRPI0510114B8 publication Critical patent/BRPI0510114B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
BRPI0510114A 2004-05-20 2005-05-19 cristais do composto 4-oxoquinolina, cristais misturados e composição farmacêutica BRPI0510114B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004-150979 2004-05-20
JP2004150979 2004-05-20
PCT/JP2005/009604 WO2005113508A1 (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound

Publications (3)

Publication Number Publication Date
BRPI0510114A BRPI0510114A (pt) 2007-09-25
BRPI0510114B1 BRPI0510114B1 (pt) 2020-09-15
BRPI0510114B8 true BRPI0510114B8 (pt) 2021-05-25

Family

ID=35079161

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510114A BRPI0510114B8 (pt) 2004-05-20 2005-05-19 cristais do composto 4-oxoquinolina, cristais misturados e composição farmacêutica

Country Status (33)

Country Link
US (7) US7635704B2 (https=)
EP (4) EP1636190B1 (https=)
JP (1) JP3754064B2 (https=)
KR (1) KR20080064909A (https=)
CN (1) CN1956961B (https=)
AR (2) AR049280A1 (https=)
AU (1) AU2005245296B2 (https=)
BE (1) BE2024C511I2 (https=)
BR (1) BRPI0510114B8 (https=)
CA (1) CA2566922C (https=)
CY (4) CY1113010T1 (https=)
DK (2) DK1636190T3 (https=)
ES (2) ES2388441T3 (https=)
FI (2) FI3281939T3 (https=)
FR (1) FR23C1040I1 (https=)
HR (2) HRP20120681T1 (https=)
HU (2) HUE064615T2 (https=)
IL (1) IL179250A0 (https=)
LT (2) LT3281939T (https=)
LU (1) LUC00334I2 (https=)
MX (1) MXPA06013405A (https=)
MY (1) MY134672A (https=)
NO (8) NO339223B1 (https=)
NZ (1) NZ551839A (https=)
PE (2) PE20120361A1 (https=)
PL (2) PL1636190T3 (https=)
PT (2) PT3281939T (https=)
RS (2) RS64845B1 (https=)
RU (1) RU2330845C1 (https=)
SI (2) SI3281939T1 (https=)
TW (1) TWI329015B (https=)
WO (1) WO2005113508A1 (https=)
ZA (1) ZA200610647B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
SK2662004A3 (sk) * 2002-11-20 2005-06-02 Japan Tobacco, Inc. Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
EP1976517A1 (en) * 2005-12-30 2008-10-08 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP2452682A1 (en) * 2006-02-01 2012-05-16 Japan Tobacco, Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
ES2531190T3 (es) * 2006-03-06 2015-03-11 Japan Tobacco Inc Método para producir un compuesto de 4-oxoquinolina
WO2007102499A1 (ja) 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
PL2049506T5 (pl) 2006-07-07 2024-09-09 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości leków
WO2008033836A2 (en) 2006-09-12 2008-03-20 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
MX2009008935A (es) 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
US20100331331A1 (en) * 2007-06-29 2010-12-30 Therapeutic Compositons And Use Thereof Therapeutic compositions and the use thereof
AR067184A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
EP2393485B1 (en) 2009-02-06 2015-07-29 Gilead Sciences, Inc. Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
AU2013296289B2 (en) 2012-08-03 2017-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
NO2865735T3 (https=) 2013-07-12 2018-07-21
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (https=) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536B1 (en) * 2020-10-19 2025-06-25 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (https=) 1970-09-14 1981-02-16
JPS4826772A (https=) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
NO304832B1 (no) * 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
KR970704693A (ko) * 1994-07-18 1997-09-06 나가히로 마오미 트리플루오로메틸퀴놀린카르복실산 유도체(trifluoromethylquinolinecarboxylic acid derivative)
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
ATE211471T1 (de) 1996-04-12 2002-01-15 Us Gov Health & Human Serv Acridonderivate als antineoplastische-und antiretrovirale mittel
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) * 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6248736B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
PE20011349A1 (es) * 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
ATE345129T1 (de) 2000-10-12 2006-12-15 Merck & Co Inc Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
WO2002036734A2 (en) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
JP3616628B2 (ja) * 2001-03-01 2005-02-02 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する含窒素芳香族複素環化合物
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
RU2206564C1 (ru) * 2002-03-07 2003-06-20 Общество с ограниченной ответственностью "Поливит" Способ получения этилового эфира 6-фтор-7-хлор-1,4-дигидро-4-оксо-3-хинолинкарбоновой кислоты
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
SK2662004A3 (sk) * 2002-11-20 2005-06-02 Japan Tobacco, Inc. Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
EP1758581A1 (en) * 2004-05-21 2007-03-07 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents

Also Published As

Publication number Publication date
AR096100A2 (es) 2015-12-09
CY2015009I2 (el) 2024-09-20
DK1636190T3 (da) 2012-09-24
NO20200873A1 (no) 2007-02-07
NO20230913A1 (no) 2007-02-07
TW200600097A (en) 2006-01-01
BRPI0510114A (pt) 2007-09-25
US20180029989A1 (en) 2018-02-01
RS52375B (sr) 2012-12-31
AU2005245296A1 (en) 2005-12-01
PE20120361A1 (es) 2012-05-03
JP2006001927A (ja) 2006-01-05
FR23C1040I1 (fr) 2023-12-29
CY2024008I2 (el) 2024-09-20
HRP20231588T3 (hr) 2024-03-15
US7635704B2 (en) 2009-12-22
PL1636190T3 (pl) 2012-10-31
NZ551839A (en) 2009-11-27
LUC00334I2 (https=) 2024-07-01
HUS2400006I1 (hu) 2024-04-28
ES2960824T3 (es) 2024-03-06
LT3281939T (lt) 2023-11-27
ZA200610647B (en) 2008-06-25
AU2005245296B2 (en) 2010-08-12
EP4299563A3 (en) 2024-02-28
JP3754064B2 (ja) 2006-03-08
PE20060358A1 (es) 2006-05-12
CA2566922C (en) 2011-01-11
US8981103B2 (en) 2015-03-17
EP4299563A2 (en) 2024-01-03
HRP20120681T1 (hr) 2012-09-30
NO20220690A1 (no) 2007-02-07
FI3281939T3 (fi) 2023-10-23
ES2388441T3 (es) 2012-10-15
US20250091995A1 (en) 2025-03-20
CY1113010T1 (el) 2016-04-13
KR20080064909A (ko) 2008-07-09
AR049280A1 (es) 2006-07-12
BE2024C511I2 (https=) 2024-10-08
CN1956961B (zh) 2010-05-26
TWI329015B (en) 2010-08-21
BRPI0510114B1 (pt) 2020-09-15
CN1956961A (zh) 2007-05-02
EP1636190A1 (en) 2006-03-22
DK3281939T3 (da) 2024-01-22
IL179250A0 (en) 2007-03-08
US20100204271A1 (en) 2010-08-12
RU2330845C1 (ru) 2008-08-10
LTPA2024001I1 (https=) 2024-04-10
EP3281939B1 (en) 2023-10-18
EP3281939A1 (en) 2018-02-14
NO20161297A1 (no) 2007-02-07
US20220235009A1 (en) 2022-07-28
WO2005113508A1 (en) 2005-12-01
US20060030710A1 (en) 2006-02-09
MY134672A (en) 2007-12-31
HK1083341A1 (en) 2006-06-30
CA2566922A1 (en) 2005-12-01
NO339223B1 (no) 2016-11-21
HUE064615T2 (hu) 2024-04-28
PT3281939T (pt) 2023-11-22
SI1636190T1 (sl) 2012-09-28
SI3281939T1 (sl) 2024-02-29
US20150361044A1 (en) 2015-12-17
MXPA06013405A (es) 2007-03-01
EP2514746A1 (en) 2012-10-24
PL3281939T3 (pl) 2024-03-18
CY2015009I1 (el) 2024-09-20
RS64845B1 (sr) 2023-12-29
NO20065790L (no) 2007-02-07
NO347902B1 (no) 2024-05-06
PT1636190E (pt) 2012-08-20
FIC20240008I1 (fi) 2024-03-20
NO20240384A1 (no) 2007-02-07
EP1636190B1 (en) 2012-06-27
NO20190051A1 (no) 2007-02-07
CY1126560T1 (el) 2024-09-20
US20190185433A1 (en) 2019-06-20
LTC3281939I2 (https=) 2025-04-25
NO2024034I1 (no) 2024-07-15
CY2024008I1 (el) 2024-09-20

Similar Documents

Publication Publication Date Title
BRPI0510114B8 (pt) cristais do composto 4-oxoquinolina, cristais misturados e composição farmacêutica
SG170069A1 (en) Quinoline derivatives
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
HN2009000784A (es) Dihidropirazolonas sustituidas
MY170189A (en) 6-cycloalkyl-1, 5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
BR112013003864A2 (pt) compostos de pirrolpirimidina e usos dos mesmos
BR112013004368A2 (pt) compostos tendo a fórmula geral (i) e composição farmacêutica
UY27604A1 (es) Compuestos químicos.
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
BR112013002587A2 (pt) compostos químicos
BRPI0410660A (pt) derivados de 2-amino-piridina como agonistas de adrenoreceptor ß2
BR112015012366A2 (pt) antagonistas de cxcr7
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
MX2009011421A (es) Derivados de ftalazina e isoquinolina con actividades moduladoras del receptor de la s1p.
WO2006126939A8 (en) Novel 8-sulfonylamino-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor
EA201000434A1 (ru) Сокристаллы пириметанила и дитианона
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
ATE478858T1 (de) Cyclische sulfone, die zur verwendung als bace- inhibitoren geeignet sind
BR112015012752A2 (pt) derivados de amino ciclo butano, o respectivo processo de preparo e a respectiva utilização a título de medicamentos
GB0517175D0 (en) Compounds
WO2007065662A3 (en) Trisubstituted quinazolinone derivatives as vanilloid antagonists
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
TW200745085A (en) Quinoline derivatives

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: JAPAN TOBACCO, INC. (JP)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.